Related Experiment Videos
Small molecular anti-cytokine agents.
1School of Chemical Sciences and Pharmacy, University of East Anglia, Norwich, NR4 7TJ, England.
Medicinal Research Reviews
|November 12, 2005
Summary
Small-molecule inhibitors targeting p38 MAP kinase, TACE, and ICE are being developed as alternatives to anti-cytokine biologics. This review examines their molecular targets and cellular activity for treating inflammatory diseases.
Area of Science:
- Pharmacology
- Molecular Biology
- Drug Discovery
Background:
- Anti-cytokine biologics like Etanercept have shown success.
- This has driven research into small-molecule anti-cytokine agents.
- Key molecular targets include p38 MAP kinase, TACE, and ICE.
Purpose of the Study:
- To review small-molecule inhibitors targeting p38 MAP kinase, TACE, and ICE.
- To highlight the correlation between molecular inhibition and cellular activity.
- To discuss structure-activity relationships for in vitro and in vivo efficacy.
Main Methods:
- Review of in vitro characterized inhibitors of p38 MAP kinase, TACE, and ICE.
- Analysis of functional assays for cytokine production (TNF-alpha, IL-1beta).
- Discussion of structure-activity relationships (SAR) and drug-like properties.
Main Results:
- Numerous inhibitors for p38 MAP kinase, TACE, and ICE have been identified.
- Some inhibitors have progressed to clinical trials.
- Correlation between target inhibition and cellular activity is crucial.
Conclusions:
- Small-molecule inhibitors targeting p38 MAP kinase, TACE, and ICE represent a promising therapeutic strategy.
- Further research into SAR is needed for optimized drug development.
- These agents could offer alternatives to biologics for inflammatory conditions.